Want to see HK:1530 full AI Analyst Report?
Top Page
3SBio
(1530)
Select Model
Select Model
Rating:69Neutral
Price Target:
HK$20.00
▼(-20.82% Downside)
Action:Downgraded
Date:06/05/26
The score is supported by very strong 2025 financial performance and an inexpensive valuation (low P/E), but is pulled down by clearly negative technical momentum (price below major moving averages and negative MACD). The main fundamental caveat is whether the exceptional 2025 profitability and cash generation are durable given prior-year volatility.
Positive Factors
2025 revenue & profitability
A large, simultaneous increase in top-line and extremely high sector-leading margins in 2025 indicates the company achieved strong product mix, pricing or manufacturing leverage. If sustained, these margins support reinvestment, R&D, and strong returns on incremental sales over the medium term.
Negative Factors
Historic earnings volatility
Prior multi-year variability in revenue growth, margins and cash conversion undermines predictability of performance. For a biologics commercial platform, such volatility signals exposure to timing of approvals, tender cycles, or product mix shifts that can materially alter earnings and cashflow over several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
2025 revenue & profitability
A large, simultaneous increase in top-line and extremely high sector-leading margins in 2025 indicates the company achieved strong product mix, pricing or manufacturing leverage. If sustained, these margins support reinvestment, R&D, and strong returns on incremental sales over the medium term.
Read all positive factors
3SBio (1530) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$45.86B
Dividend Yield0.95%
Average Volume (3M)31.12M
Price to Earnings (P/E)4.6
Beta (1Y)0.91
Revenue Growth95.27%
EPS Growth304.20%
CountryHK
Employees5,577
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.41
Shares Outstanding2,538,084,500
10 Day Avg. Volume32,899,411
30 Day Avg. Volume31,124,824
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.97
Price to Sales (P/S)3.03
P/FCF Ratio5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$36.44Price Target Upside44.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.05
Revenue Forecast (FY)HK$10.13B
3SBio Business Overview & Revenue Model
Company Description
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse port...
How the Company Makes Money
3SBio primarily makes money by selling prescription pharmaceuticals—especially biologic drugs—into the Chinese healthcare market. Its core revenue stream is product sales: the company manufactures and commercializes its own branded medicines (incl...
3SBio Financial Statement Overview
Summary
Income Statement
92
Very Positive
Balance Sheet
84
Very Positive
Cash Flow
88
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.70B | 9.11B | 7.82B | 6.86B | 6.38B |
| Gross Profit | 16.35B | 7.83B | 6.64B | 5.67B | 5.28B |
| EBITDA | 11.00B | 2.93B | 2.53B | 2.75B | 2.26B |
| Net Income | 8.48B | 2.09B | 1.55B | 1.92B | 1.65B |
Balance Sheet | |||||
| Total Assets | 36.27B | 24.21B | 23.63B | 21.99B | 19.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.73B | 5.79B | 5.99B | 7.01B | 4.70B |
| Total Debt | 2.62B | 3.55B | 4.84B | 4.52B | 2.63B |
| Total Liabilities | 5.82B | 6.18B | 7.11B | 6.59B | 4.55B |
| Stockholders Equity | 27.22B | 15.44B | 14.03B | 12.96B | 12.23B |
Cash Flow | |||||
| Free Cash Flow | 9.13B | 2.24B | 1.38B | 1.21B | 432.57M |
| Operating Cash Flow | 9.67B | 3.20B | 2.08B | 2.18B | 1.58B |
| Investing Cash Flow | -1.83B | -1.36B | -1.35B | -3.72B | -1.29B |
| Financing Cash Flow | 2.35B | -2.25B | -352.98M | 763.22M | -481.12M |
3SBio Technical Analysis
Neutral
25.26
Price Trends
18.51
Negative
20.68
Negative
24.46
Negative
Market Momentum
<0.01
Negative
52.40
Neutral
37.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1530, the sentiment is Neutral. The current price of 25.26 is above the 20-day moving average (MA) of 17.10, above the 50-day MA of 18.51, and above the 200-day MA of 24.46, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.40 is Neutral, neither overbought nor oversold. The STOCH value of 37.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1530.
3SBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | HK$45.86B | 4.57 | 38.96% | 0.95% | 95.27% | 304.20% | |
64 Neutral | HK$157.29B | 27.53 | 10.64% | ― | 16.79% | 47.14% | |
61 Neutral | HK$34.29B | 35.71 | 23.99% | ― | 16.65% | 0.87% | |
52 Neutral | HK$72.28B | 58.78 | 42.27% | ― | 80.08% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$89.58B | -68.79 | -14.26% | ― | 44.03% | -108.83% | |
42 Neutral | HK$38.29B | -57.85 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1530
3SBio
18.07
-9.91
-35.41%
HK:2269
Wuxi Biologics (Cayman)
37.96
11.21
41.91%
HK:9926
Akeso, Inc.
97.25
-20.95
-17.72%
HK:9995
RemeGen Co. Ltd. Class H
84.10
20.15
31.51%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
19.37
-4.03
-17.22%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
62.90
10.75
20.61%
3SBio Corporate Events
3SBio Shareholders Approve Dividend and Auditor Change at AGM
Jun 25, 2026
Shareholders of 3SBio Inc. approved all resolutions at the annual general meeting held on 25 June 2026, including the adoption of the 2025 audited financial statements and the re-election of two independent non-executive directors. Voting was cond...
3SBio Sets June 2026 AGM to Approve Dividend, New Auditor and Share Issue Mandate
Jun 3, 2026
3SBio Inc., a Cayman Islands–incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange, plans to convene its annual general meeting on 25 June 2026 in Shenyang, China. The meeting underscores the company’s ongoing g...
3SBio Moves to Replace Long-Standing Auditor EY With KPMG at 2026 AGM
May 26, 2026
3SBio has proposed replacing its long-serving auditor Ernst Young, which has handled the company’s audits for more than 15 years, with KPMG following the conclusion of the 2026 annual general meeting, citing good corporate governance practi...
3SBio Shareholders Back Spin-Off Dividend of Mandi Inc. Shares
Apr 23, 2026
3SBio shareholders have approved an ordinary resolution at an extraordinary general meeting held on 23 April 2026 to distribute all shares of subsidiary Mandi Inc. as a conditional special dividend in specie. The vote, overseen by Computershare Ho...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.